BURLINGTON, ON, June 6, 2024 /PRNewswire/ - EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD). The results demonstrated efficacy for a subset of patients suffering from moderate to severe SAD. These results will guide further clinical research and the design of a robust Phase 3 program.
London Research & Pharmaceuticals Corp. Presents the Advancement of their Oral Cannabidiol Sulphate Drug Candidate at Epilepsy Therapies Conference
Harmony is paying $60 million in cash for Zynerba, with another $140 million on the table in the form of a contingent value right (CVR) if Zygel makes it through development and registration as predicted and meets various sales targets, including an aggregate of $500 million net revenues by mid-2025.
SILVER SPRING, Md., Jan. 26, 2023 /PRNewswire/ -- Given the growing cannabidiol (CBD) products market, the U.S. Food and Drug Administration convened a high-level internal working group to explore potential regulatory pathways for CBD products. Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals' desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter. Today, we are also denying three citizen petitions that had asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.
Transo-Pharm establishes relationship with 22nd Century Group as their partner for Global Sales, Marketing, and Distribution of Pharmaceutical Grade Cannabinoid APIs
Pharma companies routinely sue generics makers for alleged patent infringement with their proposed copycats. But the fight over Jazz Pharmaceuticals' Epidiolex marks a more unique fight against pending generic competition.
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
FDA Confirms Paragraph IV Patent Litigation for Cannabidiol Oral Solution
DUBLIN, Dec. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex® (cannabidiol) oral solution reported improvements in patients' seizure and non-seizure outcomes across all age groups.1,2 These data were presented at the 2022 American Epilepsy Society (AES) annual meeting taking place December 2–6, 2022, in Nashville, TN.
PureTech Health has spied an opportunity to improve on Jazz Pharmaceuticals’ Epidiolex. Armed with its Glyph chemistry platform, the biotech has created an oral capsule formulation of cannabidiol (CBD) that it plans to take into the clinic late next year.